Study | Study design | Group | N | Male (n) | GA (wk) | BW (g) | Antenatal steroid | Surfactant (n) | Caffeine (n) |
---|---|---|---|---|---|---|---|---|---|
Bottino 2018 [20] | Randomized controlled crossover trial | nHFOV | 15 | NA | < 32 | < 1500 | NA | 15 | 15 |
nCPAP | 15 | NA | < 32 | < 1500 | NA | 15 | 15 | ||
Klotz 2017 [16] | Randomized controlled crossover trial | nHFOV | 13 | 2 | 26.1 (2.2)* | 814.2 (208.2)* | 13 | 13 | 13 |
nCPAP | 13 | 9 | 27.2 (2.0)* | 1083.5 (359.1)* | 13 | 13 | 13 | ||
Lou 2017 [21] | Randomized controlled trial | nHFOV | 34 | 24 | 32.5 (1.3)* | 1790 (350)* | 13 | 34 | NA |
nCPAP | 31 | 22 | 32.4 (1.4)* | 1850 (410)* | 12 | 21 | NA | ||
Lou 2018 [22] | Randomized controlled trial | nHFOV | 33 | 18 | 33.5 (1.5)* | 1790 (330)* | 12 | 33 | NA |
BPCPAP | 32 | 17 | 34.2 (1.6)* | 1840 (420)* | 11 | 32 | NA | ||
Malakian 2018 [23] | Randomized controlled trial | nHFOV | 63 | 28 | 31.08 (2.9)* | 1485.5 (470)* | 36 | 21 | NA |
nCPAP | 61 | 25 | 31.07 (2.8)* | 1505.5 (490)* | 31 | 23 | NA | ||
Mukerji 2017 [24] | Randomized controlled trial | nHFOV | 16 | 1 | 26.1 (1.3)* | 831.9 (150.1)* | 12 | 10 | NA |
BPCPAP | 23 | 2 | 26.5 (1.6)* | 878.0 (198.3)* | 20 | 14 | NA | ||
Zhu 2017 [25] | Randomized controlled trial | nHFOV | 37 | 22 | 31.7 (1.7)* | 1670 (353)* | 13 | 37 | NA |
nCPAP | 39 | 21 | 32.0 (1.9)* | 1735 (327)* | 15 | 39 | NA | ||
Zhu 2017 [26] | Randomized controlled trial | nHFOV | 17 | 10 | 31.7 (1.7)* | 1670 (353)* | 6 | 17 | NA |
nCPAP | 21 | 12 | 32.0 (1.9)* | 1735 (327)* | 8 | 21 | NA |